PubMed Health⌕ Search

PubMed · 16808468

Modulation ratio in comprehensive two-dimensional gas chromatography.

Abstract

Comprehensive two-dimensional chromatography employs a serially coupled two-column arrangement where effluent from the first column is collected or sampled and then introduced to the second column according to a chosen modulation period. This is effected by use of a modulator at or near the column junction. One of the considerations in applying the technique is the period of the modulator, which determines the sampling duration of the first column effluent. Here, we propose that the sampling rate can be most effectively described by a new term, called the modulation ratio (MR). This is defined as the ratio of 4 times the first column peak standard deviation (4sigma) divided by the modulation period (PM) or 1.6985 times the half-height width of the peak (wh): MR = 4sigma/PM = wb/PM = (wh x 1.6985)/PM. The 4sigma value is more commonly recognized as the peak base width (wb). The use of 4sigma as the numerator is preferred to simply sigma because when the PM value used for an experiment is equal to sigma, then the MR value is calculated to be 4, implying that the primary peak will be modulated approximately 4 times as is normally recommended for a comprehensive multidimensional separation. The less well-defined term of modulation number (NM) has been previously used and proposed as the number of modulations per peak and, therefore, is intended to convey the manner in which the primary column peak is sampled; this is a subjective and not well-characterized value. The use of MR should provide users with a meaningful and strictly defined value when reporting experimental conditions. The utility of MR is demonstrated through a mathematical model of the modulation process for both Gaussian and tailing peaks, supported by an experimental study of the modulation ratio. It is shown that for the analysis of trace compounds where precise quantitative measurements are being made, the experiment should be conducted with an MR of at least 3. Conversely, for semiquantitative methods or the analysis of major components, an MR of approximately 1.5 should suffice.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Weeraya Khummueng, James Harynuk, Philip J Marriott. 2006-07-01. Modulation ratio in comprehensive two-dimensional gas chromatography.. https://doi.org/10.1021/ac052270b

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗